J Virol. 1992 August; 66(8): 4720-4731
Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor.
A Opgenorth,
K Graham,
N Nation,
D Strayer and
G McFadden
Department of Biochemistry, University of Alberta, Edmonton, Canada.
ABSTRACT
Myxoma virus (MYX) is a leporipoxvirus of rabbits that induces a lethal syndrome characterized by disseminated tumorlike lesions, generalized immunosuppression, and secondary gram-negative bacterial infection. A MYX deletion mutant (vMYX-GF- delta M11L) was constructed to remove the entire myxoma growth factor (MGF) coding sequence and that for the C-terminal five amino acids of the partially overlapping upstream gene, M11L. Unexpectedly, this deletion completely abrogates the capacity of MYX to cause the characteristic disease symptoms of myxomatosis. Upon inoculation of rabbits with vMYX-GF- delta M11L, recipient animals developed only a benign, localized nodule reminiscent of a Shope fibroma virus-induced tumor in which a single primary lesion appeared at the site of injection and then completely regressed within 14 days, leaving the animals resistant to challenge with wild-type MYX. No evidence of the purulent conjunctivitis and rhinitis that always accompany wild-type MYX infection was observed. To ascertain whether the attenuation observed in vMYX-GF- delta M11L was due to a combined effect of the MGF deletion and alteration of the upstream M11L gene, two additional MYX recombinants were constructed: an MGF- virus (vMYX-GF-) containing an intact M11L gene and an M11L- virus (vMYX-M11L-) containing an intact MGF gene. Infection with vMYX-GF- resulted in moderated symptoms of myxomatosis, but all clinical stages of the disease were still detectable. In contrast, disruption of M11L alone dramatically reduced the virus virulence, resulting in a nonlethal syndrome whose clinical course was nevertheless distinct from that of vMYX-GF- delta M11L. Upon inoculation with vMYX-M11L-, rabbits developed primary and secondary tumors which were larger and more circumscribed than those of wild-type MYX recipients. Whereas wild-type MYX infection always includes severe, purulent conjunctivitis and rhinitis, vMYX-M11L- recipients remained healthy and displayed only minimal signs of respiratory distress. By about 30 days after infection, the tumors induced by vMYX-M11L- had completely regressed and these animals were immune to challenge with wild-type MYX. Histological analysis indicated that tumors induced by vMYX-M11L- are much more heavily infiltrated with macrophages and heterophils and that the sites of viral replication are more edematous and necrotic than those of wild-type infection, suggesting that the host was able to mount a more vigorous inflammatory response to vMYX-M11L- infection.(ABSTRACT TRUNCATED AT 400 WORDS)
J Virol. 1992 August; 66(8): 4720-4731
This article has been cited by other articles:
-
Pignolet, B., Boullier, S., Gelfi, J., Bozzetti, M., Russo, P., Foulon, E., Meyer, G., Delverdier, M., Foucras, G., Bertagnoli, S.
(2008). Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants. J. Gen. Virol.
89: 1371-1379
[Abstract]
[Full Text]
-
Lun, X. Q., Zhou, H., Alain, T., Sun, B., Wang, L., Barrett, J. W., Stanford, M. M., McFadden, G., Bell, J., Senger, D. L., Forsyth, P. A.
(2007). Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. Cancer Res.
67: 8818-8827
[Abstract]
[Full Text]
-
Douglas, A. E., Corbett, K. D., Berger, J. M., McFadden, G., Handel, T. M.
(2007). Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2. Protein Sci.
16: 695-703
[Abstract]
[Full Text]
-
Werden, S. J., Barrett, J. W., Wang, G., Stanford, M. M., McFadden, G.
(2007). M-T5, the Ankyrin Repeat, Host Range Protein of Myxoma Virus, Activates Akt and Can Be Functionally Replaced by Cellular PIKE-A. J. Virol.
81: 2340-2348
[Abstract]
[Full Text]
-
Stanford, M. M., Barrett, J. W., Nazarian, S. H., Werden, S., McFadden, G.
(2007). Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells. J. Virol.
81: 1251-1260
[Abstract]
[Full Text]
-
Barrett, J. W., Sypula, J., Wang, F., Alston, L. R., Shao, Z., Gao, X., Irvine, T. S., McFadden, G.
(2007). M135R Is a Novel Cell Surface Virulence Factor of Myxoma Virus. J. Virol.
81: 106-114
[Abstract]
[Full Text]
-
Wang, G., Barrett, J. W., Stanford, M., Werden, S. J., Johnston, J. B., Gao, X., Sun, M., Cheng, J. Q., McFadden, G.
(2006). Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. USA
103: 4640-4645
[Abstract]
[Full Text]
-
Su, J., Wang, G., Barrett, J. W., Irvine, T. S., Gao, X., McFadden, G.
(2006). Myxoma Virus M11L Blocks Apoptosis through Inhibition of Conformational Activation of Bax at the Mitochondria. J. Virol.
80: 1140-1151
[Abstract]
[Full Text]
-
Wasilenko, S. T., Banadyga, L., Bond, D., Barry, M.
(2005). The Vaccinia Virus F1L Protein Interacts with the Proapoptotic Protein Bak and Inhibits Bak Activation. J. Virol.
79: 14031-14043
[Abstract]
[Full Text]
-
Johnston, J. B., Wang, G., Barrett, J. W., Nazarian, S. H., Colwill, K., Moran, M., McFadden, G.
(2005). Myxoma Virus M-T5 Protects Infected Cells from the Stress of Cell Cycle Arrest through Its Interaction with Host Cell Cullin-1. J. Virol.
79: 10750-10763
[Abstract]
[Full Text]
-
Cameron, C. M., Barrett, J. W., Liu, L., Lucas, A. R., McFadden, G.
(2005). Myxoma Virus M141R Expresses a Viral CD200 (vOX-2) That Is Responsible for Down-Regulation of Macrophage and T-Cell Activation In Vivo. J. Virol.
79: 6052-6067
[Abstract]
[Full Text]
-
Sabourdy, F., Casteignau, A., Gelfi, J., Deceroi, S., Delverdier, M., Messud-Petit, F. L.
(2004). Tumorigenic poxviruses: growth factors in a viral context?. J. Gen. Virol.
85: 3597-3606
[Abstract]
[Full Text]
-
Wang, G., Barrett, J. W., Nazarian, S. H., Everett, H., Gao, X., Bleackley, C., Colwill, K., Moran, M. F., McFadden, G.
(2004). Myxoma Virus M11L Prevents Apoptosis through Constitutive Interaction with Bak. J. Virol.
78: 7097-7111
[Abstract]
[Full Text]
-
Johnston, J. B., Barrett, J. W., Chang, W., Chung, C.-S., Zeng, W., Masters, J., Mann, M., Wang, F., Cao, J., McFadden, G.
(2003). Role of the Serine-Threonine Kinase PAK-1 in Myxoma Virus Replication. J. Virol.
77: 5877-5888
[Abstract]
[Full Text]
-
Everett, H., Barry, M., Sun, X., Lee, S. F., Frantz, C., Berthiaume, L. G., McFadden, G., Bleackley, R. C.
(2002). The Myxoma Poxvirus Protein, M11L, Prevents Apoptosis by Direct Interaction with the Mitochondrial Permeability Transition Pore. J. Exp. Med.
196: 1127-1140
[Abstract]
[Full Text]
-
Everett, H., Barry, M., Lee, S. F., Sun, X., Graham, K., Stone, J., Bleackley, R. C., McFadden, G.
(2000). M11L: A Novel Mitochondria-localized Protein of Myxoma Virus That Blocks Apoptosis of Infected Leukocytes. J. Exp. Med.
191: 1487-1498
[Abstract]
[Full Text]
-
Bárcena, J., Morales, M., Vázquez, B., Boga, J. A., Parra, F., Lucientes, J., Pagès-Manté, A., Sánchez-Vizcaíno, J. M., Blasco, R., Torres, J. M.
(2000). Horizontal Transmissible Protection against Myxomatosis and Rabbit Hemorrhagic Disease by Using a Recombinant Myxoma Virus. J. Virol.
74: 1114-1123
[Abstract]
[Full Text]
-
Lalani, A. S., Masters, J., Zeng, W., Barrett, J., Pannu, R., Everett, H., Arendt, C. W., McFadden, G.
(1999). Use of Chemokine Receptors by Poxviruses. Science
286: 1968-1971
[Abstract]
[Full Text]
-
Jackson, R. J., Hall, D. F., Kerr, P. J.
(1999). Myxoma Virus Encodes an alpha 2,3-Sialyltransferase That Enhances Virulence. J. Virol.
73: 2376-2384
[Abstract]
[Full Text]
-
Messud-Petit, F., Gelfi, J., Delverdier, M., Amardeilh, M.-F., Py, R., Sutter, G., Bertagnoli, S.
(1998). Serp2, an Inhibitor of the Interleukin-1beta -Converting Enzyme, Is Critical in the Pathobiology of Myxoma Virus. J. Virol.
72: 7830-7839
[Abstract]
[Full Text]
-
Schreiber, M., Rajarathnam, K., McFadden, G.
(1996). Myxoma Virus T2 Protein, a Tumor Necrosis Factor (TNF) Receptor Homolog, Is Secreted as a Monomer and Dimer That Each Bind Rabbit TNFalpha , but the Dimer Is a More Potent TNF Inhibitor. J. Biol. Chem.
271: 13333-13341
[Abstract]
[Full Text]
-
Mossman, K., Upton, C., McFadden, G.
(1995). The Myxoma Virus-soluble Interferon-[IMAGE] Receptor Homolog, M-T7, Inhibits Interferon-[IMAGE] in a Species-specific Manner. J. Biol. Chem.
270: 3031-3038
[Abstract]
[Full Text]
-
Seet, B. T., Barrett, J., Robichaud, J., Shilton, B., Singh, R., McFadden, G.
(2001). Glycosaminoglycan Binding Properties of the Myxoma Virus CC-chemokine Inhibitor, M-T1. J. Biol. Chem.
276: 30504-30513
[Abstract]
[Full Text]
Copyright © 1992 by the American Society for Microbiology. All rights reserved.